Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications... Show more
Enanta Pharmaceuticals is a clinical-stage biotechnology company applying a chemistry-driven drug discovery platform to viral infections and immunological diseases. Its positioning is distinctive: the company is pursuing what could become the first approved oral antiviral therapy for respiratory syncytial virus (RSV), a condition for which no antiviral treatment is currently approved, while simultaneously building an immunology franchise aimed at the type 2 immune response.
The lead RSV asset, zelicapavir, is an oral, once-daily N-protein inhibitor that generated clinically meaningful symptom-resolution and hospitalization-reduction signals in Phase 2 trials. A second RSV candidate, EDP-323, can be used alone or in combination to potentially broaden the treatment window. On the immunology side, EDP-978 targets KIT, a receptor tyrosine kinase implicated in mast-cell-driven diseases such as chronic spontaneous urticaria, while EPS-3903 targets STAT6, a signaling protein central to inflammatory pathways addressed by injectable biologics like dupilumab. A third program targets MRGPRX2, a G-protein-coupled receptor (GPCR) expressed on mast cells.
This structure gives Enanta a medium-term competitive edge in oral convenience—an attribute that could differentiate it from injected antibody therapies—though it also carries the execution risk typical of clinical-stage biotech, where value remains contingent on successful trial readouts and regulatory alignment.
Enanta's near-term outlook is unusually catalyst-dense. The company expects topline data from the Phase 1 study of EDP-978 in the fourth quarter of 2026, a readout that could validate the oral KIT inhibitor's safety and pharmacokinetic profile and shape enthusiasm for the broader immunology pipeline. In virology, Enanta plans to initiate RESOLVE, a registrational Phase 2b/3 trial of zelicapavir in high-risk adults, in the fourth quarter, with initial Phase 2b data anticipated in 2027.
Additional milestones include an IND filing for EPS-3903 and nomination of an MRGPRX2 development candidate in the second half of 2026, along with alignment with the U.S. Food and Drug Administration (FDA) on the adult Phase 3 design for zelicapavir. Patent litigation against Pfizer represents a separate catalyst: the U.S. Court of Appeals for the Federal Circuit affirmed a lower-court invalidity ruling, and Enanta has filed for rehearing, while a Unified Patent Court hearing was scheduled for late September 2026.
Analyst sentiment has remained broadly constructive. H.C. Wainwright has repeatedly reiterated a Buy rating with a $20 price target, JPMorgan initiated coverage at Overweight with a $17 target in late 2025, and Jefferies upgraded the stock to Buy in October 2025. Consensus estimates cluster around a "Moderate Buy" to "Strong Buy" rating, with published 12-month price targets generally ranging from roughly $17 to $28. These figures are external analyst expectations, not forecasts by this article.
Enanta operates at the intersection of two industry trends: the large, underserved antiviral market and the rapid growth of oral small-molecule therapies for inflammatory disease. RSV remains a substantial unmet need, particularly in infants, older adults, and patients with comorbidities, and an approved oral antiviral could command meaningful attention from physicians and payers.
Macroeconomic forces matter primarily through capital-markets channels. As a company that generates limited commercial revenue—chiefly royalties from AbbVie's MAVYRET and MAVIRET hepatitis C virus (HCV) franchise—Enanta depends on external funding to advance its pipeline. Persistent interest-rate levels, inflation trends, and broader risk appetite in the biotechnology sector can influence financing costs, dilution risk, and valuation multiples for pre-revenue drug developers. Regulatory policy, including the FDA's posture toward accelerated pathways and trial-design alignment, is a direct driver of the timeline to potential approval.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, ETF (exchange-traded fund), or other asset may trend bullish, bearish, or sideways over the next week or month. It is built to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. Investors monitoring Enanta's upcoming clinical readouts may find value in pairing fundamental analysis with such data-driven signals.
Looking toward 2026 and beyond, Enanta's trajectory hinges on converting a broad early-stage pipeline into late-stage clinical proof. The zelicapavir RESOLVE program, with initial data expected in 2027, is the central long-term value driver: success in a registrational setting could position Enanta as a first mover in the RSV antiviral market and unlock partnership or commercialization optionality.
In immunology, the EDP-978 readout and the progression of EPS-3903 toward the clinic will test whether Enanta can translate its chemistry platform beyond virology. Margin sustainability and cost structure will depend on disciplined capital allocation and the company's cash runway relative to milestone timing. Competitive threats include rival RSV programs and entrenched injectable biologics in inflammation, while regulatory developments and the outcome of the Pfizer litigation could materially alter both near-term sentiment and longer-term royalty economics. Consensus analyst expectations—centered on Buy ratings and price targets above recent levels—suggest the market is pricing in meaningful optionality, but that optionality remains contingent on successful execution across multiple, still-unproven programs.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EVNT | 12.49 | 0.01 | +0.08% |
| AltShares Event-Driven ETF (EVNT) | |||
| DBEU | 55.29 | -0.63 | -1.14% |
| Xtrackers MSCI Europe Hedged Equity ETF (DBEU) | |||
| AVLV | 93.16 | -1.31 | -1.39% |
| Avantis U.S. Large Cap Value ETF (AVLV) | |||
| SYZ | 28.58 | -0.44 | -1.53% |
| Lazard US Systematic Small Cap Equity ETF (SYZ) | |||
| GTEK | 46.14 | -2.55 | -5.25% |
| Goldman Sachs Future Tech Leaders Equity ETF (GTEK) | |||
A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with VIR. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To ENTA | 1D Price Change % | ||
|---|---|---|---|---|
| ENTA | 100% | -2.91% | ||
| VIR - ENTA | 49% Loosely correlated | -3.82% | ||
| ZYME - ENTA | 44% Loosely correlated | +0.80% | ||
| XNCR - ENTA | 44% Loosely correlated | -4.56% | ||
| ASMB - ENTA | 43% Loosely correlated | +0.80% | ||
| BCYC - ENTA | 43% Loosely correlated | -5.64% | ||
More | ||||
a developer of drugs and other pharmaceuticals products
Industry Biotechnology
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ENTA advanced for three days, in 207 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on ENTA as a result. In 60 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for ENTA just turned positive on November 09, 2026. Looking at past instances where ENTA's MACD turned positive, the stock continued to rise in 35 of 54 cases over the following month. The odds of a continued upward trend are 65%.
ENTA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 52 cases where ENTA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for ENTA entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.170) is normal, around the industry mean (3.586). P/E Ratio (-4.545) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.550) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.285) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. ENTA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.